Apeloa Pharmaceutical Co.,Ltd
000739
Rank in Stocks
#4292
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Share Price
$3.13
Market Cap
$3.62B
Change (1 day)
-1.42%
Change (1 year)
46.59%
Country
CN
Trade Apeloa Pharmaceutical Co.,Ltd (000739)
Category
Healthcare
Revenue for Apeloa Pharmaceutical Co.,Ltd (000739)
Revenue in Jun 2026 TTM: $1.33B
According to Apeloa Pharmaceutical Co.,Ltd latest financial reports the company's current revenue (TTM) is $1.33B. In 2024 the company made a revenue of $1.65B an increase over the revenue in the year 2023 that was $1.62B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Apeloa Pharmaceutical Co.,Ltd from 2000 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.33B | -4.81% |
| 2025 | $1.39B | -15.31% |
| 2024 | $1.65B | 1.61% |
| 2023 | $1.62B | 6.03% |
| 2022 | $1.53B | 8.65% |
| 2021 | $1.41B | 16.65% |
| 2020 | $1.21B | 16.48% |
| 2019 | $1.04B | 11.72% |
| 2018 | $926.93M | 8.63% |
| 2017 | $853.30M | 24.14% |
| 2016 | $687.35M | 2.89% |
| 2015 | $668.02M | -2.25% |
| 2014 | $683.37M | 7.52% |
| 2013 | $635.58M | 13.89% |
| 2012 | $558.08M | 25.04% |
| 2011 | $446.31M | 93.68% |
| 2010 | $230.44M | 15.01% |
| 2009 | $200.35M | 11.32% |
| 2008 | $179.98M | 26.18% |
| 2007 | $142.64M | -5.97% |
| 2006 | $151.70M | 18.26% |
| 2005 | $128.27M | 27.82% |
| 2004 | $100.36M | 7.83% |
| 2003 | $93.07M | 16.84% |
| 2002 | $79.66M | 364.75% |
| 2001 | $17.14M | -20.73% |
| 2000 | $21.62M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 397.95% |
IN
|
